Alternative Financing Schemes May Be Needed to Pay for Expensive New Medications
In an era of $1,000-a-pill medications, a new approach may be needed to finance an emerging breed of highly expensive pharmaceuticals and vaccines. Health care could learn from other industries, where it is common for suppliers to encourage investment through approaches such as equipment leases or supplier-financed credit.